

Influenza B Yamagata lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2024-2025 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

23 February 2024

Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI_ISL_168822

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Phuket/3073/2013	Wild type virus			WHO CCs MHRA, UK
	BVR-1B	Classical	Seqirus	VIDRL, Australia
B/California/12/2015	Wild type virus			CDC, USA
	BX-59A	Classical	NYMC	MHRA, UK NYMC, USA
	BX-59B			MHRA, UK NYMC, USA
B/Brisbane/9/2014	Wild type virus			WHO CCs MHRA, UK
B/Utah/09/2014	Wild type virus			CDC, USA MHRA, UK
B/Arizona/10/2015	BX-63	Classical	NYMC	MHRA, UK NYMC, USA
	BX-63A			MHRA, UK NYMC, USA
B/Hong Kong/3417/2014	Wild type virus			NYMC, USA MHRA, UK
	BX-57	Classical	NYMC	MHRA, UK NYMC, USA

Institutes contact details for candidate vaccine virus orders/information:

CCDC: whocc-china@cnic.org.cn

CDC: pdx1@cdc.gov (Subject: CVV request)

FCI: whocc@crick.ac.uk

MHRA: standards@nibsc.org or enquiries@nibsc.org

NIID: flu-vaccine@nih.go.jp

NYMC: doris_bucher@nymc.edu

VIDRL: whoflu@influenzacentre.org

WHO CCs and ERLs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres

¹ For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

² <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag lot number	Unitage (µg HA/ml)	Available from
	Candidate vaccine virus	Egg or cell			
B/Phuket/3073/2013	Wild type	Egg	B(y)-Ag-2112	60	CBER/FDA, USA
			21/136	66	MHRA, UK
			2023BYA	56	NIID, Japan
			2023BYB	58	
			2017/115B	85	TGA, Australia
	BVR-1B	Egg	2020/136B	86	
			2023/142B	88	

Sheep antisera

Purified HA from		Order Lot number	Available from
Parent virus	egg or cell		
B/Phuket/3073/2013-like	Egg	B(y)-Ab-2215	CBER/FDA, USA
		22/132	MHRA, UK
		2021BY-1	NIID, Japan
		AS425	TGA, Australia
		AS426	

The above-listed potency testing reagents have been developed with support from manufacturers and calibrated by the WHO Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS).

ERLs contact details for reagents orders/information:

CBER: CBERshippingrequests@fda.hhs.gov
MHRA: standards@nibsc.org or enquiries@nibsc.org
NIID: flu-vaccine@nih.go.jp
TGA: influenza.reagents@health.gov.au

For other candidate vaccine viruses and potency testing reagents, please go to <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

For general enquiries, please contact gisrs-whohq@who.int